CMS News

CMS: Next Day Disclosure Return

Apr 24 06:50 ET

CMS: Voluntary and Business Update Announcement New Drug Application of Desidustat Tablets Accepted in China

Apr 23 08:04 ET

CMS: Next Day Disclosure Return

Apr 17 07:32 ET

CMS: NOTIFICATION LETTER

Apr 17 05:18 ET

CMS: FORM OF PROXY

Apr 17 05:10 ET

CMS: Environmental, Social and Governance Report 2023

Apr 17 04:50 ET

CMS: Voluntary and Business Update Announcement New Drug Application of Ruxolitinib Cream Approved in Macau

Apr 16 10:34 ET

CMS: Next Day Disclosure Return

Apr 15 07:56 ET

CMS: Next Day Disclosure Return

Apr 12 07:28 ET

CMS: Next Day Disclosure Return

Apr 11 07:52 ET

CMS: Next Day Disclosure Return

Apr 10 07:04 ET

CMS: Next Day Disclosure Return

Apr 9 06:34 ET

CMS: Next Day Disclosure Return

Apr 8 07:35 ET

CMS: Next Day Disclosure Return

Apr 3 07:26 ET

CMS: Next Day Disclosure Return

Apr 2 07:52 ET

CMS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

Apr 2 05:33 ET

CMS: Voluntary and Business Update Announcement Gaining Exclusive License for Oral Small-molecule JAK1 Inhibitor Povorcitinib for the Treatment of Vitiligo and Hidradenitis Suppurativa and Other Indications

Apr 1 06:22 ET

CMS: VOLUNTARY ANNOUNCEMENT ADOPTION OF SHARE AWARD SCHEMES RELATED TO CMS NEW PRODUCTS

Mar 27 10:51 ET

CMS: FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2023

Mar 27 10:47 ET

CMS: Voluntary and Business Update Announcement Approval to Conduct a Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Atopic Dermatitis in China

Mar 19 08:17 ET